Fyn kinase (encoded by the FYN gene) is a member of the Src family of non-receptor tyrosine kinases (SFKs) that has emerged as a promising therapeutic target across multiple neurodegenerative diseases. Fyn connects several key pathological mechanisms including tau phosphorylation, NMDA receptor excitotoxicity, microglial activation, and alpha-synuclein phosphorylation[1].
The strategic importance of Fyn inhibition stems from its central position in multiple disease-relevant signaling cascades. Unlike single-target approaches, modulating Fyn activity addresses downstream effects of multiple upstream pathologies, making it an attractive cross-disease therapeutic strategy for Alzheimer's disease, Parkinson's disease, CBS/PSP, and ALS/FTD.
Fyn plays a critical role in AD pathogenesis through several interconnected pathways:
Tau Phosphorylation: Fyn phosphorylates tau at tyrosine residues (Tyr18, Tyr29), promoting pathological aggregation and spread[2]. This connects amyloid-beta signaling to downstream tau pathology.
NMDA Receptor Dysregulation: Fyn phosphorylates NR2A and NR2B subunits, leading to altered receptor trafficking and function. Hyperactive Fyn signaling contributes to excitotoxic cell death through excessive NMDA receptor activation.
Amyloid-beta Signaling: Aβ oligomers activate Fyn, creating a pathogenic feedback loop where amyloid pathology drives toxic downstream signaling through Fyn-dependent pathways.
Synaptic Dysfunction: Fyn-dependent phosphorylation of PSD-95 and other postsynaptic density proteins contributes to synaptic loss and cognitive decline.
In PD, Fyn participates in:
Alpha-synuclein Phosphorylation: Fyn phosphorylates α-synuclein at Tyr125, Tyr133, and Tyr136, potentially accelerating aggregation and toxicity[3].
Dopaminergic Neuron Survival: Fyn regulates dopamine receptor signaling and neurotrophic factor responses in dopaminergic neurons.
Neuroinflammation: Fyn mediates microglial activation and inflammatory cytokine production in response to pathological α-synuclein.
Fyn contributes to tau propagation and spread in tauopathies:
Tau Tyrosine Phosphorylation: Fyn-mediated tau phosphorylation at tyrosine residues facilitates misfolding and propagation of pathological tau species.
Synaptic Vulnerability: Fyn signaling at synapses may accelerate tau-induced synaptic dysfunction.
TDP-43 Pathology: Fyn may interact with TDP-43 aggregation pathways in ALS/FTD.
Synaptic Excitotoxicity: Similar to AD, Fyn-mediated NMDA receptor dysregulation contributes to excitotoxic cell death.
Saracatinib is the most advanced Fyn kinase inhibitor in clinical development for neurodegeneration:
| Property | Details |
|---|---|
| Mechanism | Dual Src/Abl kinase inhibitor |
| IC50 for Fyn | ~10 nM |
| Clinical Status | Phase II completed for AD |
| Company | AstraZeneca |
| Route | Oral |
Clinical Trial Results:
Dasatinib is an FDA-approved broad SFK inhibitor (originally for CML):
| Property | Details |
|---|---|
| Mechanism | Broad Src family kinase inhibitor |
| IC50 for Fyn | ~50 nM |
| Clinical Status | FDA-approved for CML, repurposing potential |
| Company | Bristol-Myers Squibb |
| Route | Oral |
Considerations for Neurodegeneration:
These are research-grade selective Fyn inhibitors:
| Compound | Specificity | IC50 | Status |
|---|---|---|---|
| PP1 | Src family selective | 170 nM | Research only |
| PP2 | Src family selective | ~200 nM | Research only |
Both compounds have been used extensively in preclinical models but lack the pharmaceutical properties for clinical development.
Another FDA-approved SFK inhibitor with potential for repurposing:
| Property | Details |
|---|---|
| Mechanism | Src/Abl inhibitor |
| Clinical Status | FDA-approved for CML |
| Brain Penetration | Moderate |
Fyn kinase inhibition as a single-agent therapy addresses the downstream convergence point of multiple pathological triggers. The monotherapy approach is best suited for:
Fyn modulators may be combined with:
Anti-amyloid agents (lecanemab, donanemab): Address upstream Aβ pathology while blocking downstream Fyn-dependent toxicity
Anti-tau agents: Synergistic effect on tau pathology through complementary mechanisms
Neurotrophic factors: Fyn inhibition combined with BDNF or similar agents for enhanced neuroprotection
Anti-inflammatory agents: Target microglial activation through both Fyn-dependent and independent pathways
| Strategy | Advantages | Challenges |
|---|---|---|
| Small molecule inhibitors | Oral bioavailability, BBB penetration | Selectivity, tolerability |
| Brain-penetrant prodrugs | Enhanced CNS exposure | Development complexity |
| Antisense oligonucleotides | High selectivity | Delivery, distribution |
| Trial | Compound | Indication | Phase | Status |
|---|---|---|---|---|
| NCT02167256 | Saracatinib | AD | IIa | Completed (no cognitive benefit)[4] |
| — | Dasatinib + Quercetin | ALS | — | No active trial verified |
Kaufman AC, et al. FYN kinase inhibition reduces Aβ toxicity in Alzheimer's disease. 2015. ↩︎
Nygaard HB, et al. Targeting FYN kinase in Alzheimer's disease. 2018. ↩︎
Zhou X, et al. FYN in dopaminergic neuron survival and alpha-synuclein phosphorylation. 2016. ↩︎
Forman MS, et al. The Src family kinase inhibitor saracatinib (AZD0530) in Alzheimer's disease. 2014. ↩︎